Cyclo Therapeutics, Inc. (CYTH)
- Previous Close
1.2900 - Open
1.3450 - Bid --
- Ask --
- Day's Range
1.2700 - 1.3464 - 52 Week Range
0.8900 - 2.5700 - Volume
29,181 - Avg. Volume
92,438 - Market Cap (intraday)
37.2M - Beta (5Y Monthly) -0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.20
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
cyclotherapeutics.com8
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CYTH
Performance Overview: CYTH
Trailing total returns as of 5/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTH
Valuation Measures
Market Cap
36.91M
Enterprise Value
34.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.73
Price/Book (mrq)
60.51
Enterprise Value/Revenue
30.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-143.52%
Return on Equity (ttm)
-730.48%
Revenue (ttm)
1.08M
Net Income Avi to Common (ttm)
-20.06M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
9.25M
Total Debt/Equity (mrq)
21.72%
Levered Free Cash Flow (ttm)
-8.26M
Research Analysis: CYTH
Company Insights: CYTH
CYTH does not have Company Insights
Research Reports: CYTH
Daily – Vickers Top Insider Picks for 03/10/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/09/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/07/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/03/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.